Key Takeaways
- Growth Constraints: Specialty drug prior authorization acts as a systemic ceiling, delaying treatment starts, slowing revenue realization, and limiting clinic growth.
- Dual-Path Complexity: Unlike standard scripts, specialty therapies face “dual-pathway” friction, requiring staff to navigate both medical and pharmacy benefit structures simultaneously.
- The “53 Million” Factor: Medicare Advantage plans alone processed 53 million prior authorization determinations in 2024, highlighting the scale of the issue.
- CMS-0057-F Compliance: New federal mandates effective Jan. 1, 2026, require payers to respond to urgent requests within 72 hours, shifting the pressure onto clinics to submit perfect documentation.
- Revenue Realization: Specialty practices that modernize their authorization workflows now are better positioned to convert faster payer timelines into faster revenue.
For many practices, specialty drug prior authorization has stopped feeling like a process and started feeling like a ceiling. Biologics, infused therapies, injectables, and other specialty medications often require extensive documentation before treatment can start. Days or even weeks may pass between prescribing a therapy and receiving a payer response. In the meantime, schedules shift, infusion chairs sit open, and patients wait for access to treatment their provider has already determined they need.
The scale of these problems is immense. According toKFF, Medicare Advantage insurers processed nearly 53 million prior authorization determinations in 2024 alone. Meanwhile, the American Medical Association (AMA) Prior Authorization Physician Survey found that 94% of physicians report prior authorization delays negatively affect patient care. Nearly one in four physicians said PA requirements have contributed to a serious adverse event for a patient, including hospitalization, disability, or other life-threatening outcomes.
For many practices, these delays have been absorbed as a cost of doing business. Increasingly, they function as something more significant: a systemic growth constraint.
Why Specialty Drug Prior Authorization Creates a Different Level of Friction
The insurance prior authorization process for specialty medications rarely follows a simple path. While traditional prescription authorizations may involve a single approval workflow, specialty medications often require layered clinical documentation, diagnosis validation, step therapy history, lab results, and site-of-care justification. Usually, providers must determine whether a therapy falls under the pharmacy benefit or the medical benefit before authorization work can even begin.
That distinction matters more than many practices realize.
According to Berkeley Research Group (BRG), specialty medications frequently straddle both benefit structures, creating overlapping requirements and inconsistent payer expectations. Infused and injected therapies billed under the medical benefit may follow one approval path, while self-administered specialty medications billed through the pharmacy benefit may follow another entirely.
For specialty clinics, that means staff are often navigating multiple payer portals, documentation formats, timelines, and denial criteria simultaneously. According to the MGMA 2024 Prior Authorization Issue Brief, 89% of medical groups reported prior authorization requirements as “very or extremely burdensome” — a reflection of just how much administrative and operational weight these workflows carry at the practice level.
Biologic and infusion therapy approval delays compound quickly under those conditions. A delayed authorization can postpone treatment starts, disrupt infusion scheduling, and create uncertainty around staffing and reimbursement timing. Even when approval eventually comes through, the operational disruption has already done its damage.
The result? A workflow many practices have normalized despite its growing drag on revenue realization and financial performance.
Treatment Delays and Patient Access: What the Bottleneck Actually Costs
Prior authorization delays affect more than administrative workload. They create direct financial consequences throughout the specialty practice revenue cycle. Treatment that’s clinically approved internally but financially stalled externally represents revenue that exists on paper but can’t be realized until authorization is complete and therapy begins. For high-cost biologics, infused therapies, and injectables, that gap between prescribing and payment can be significant.
For specialty practices, the revenue cycle impact compounds quickly. Delayed authorization pushes back therapy start dates, which pushes back claim submission, which pushes back reimbursement. When that pattern repeats across a high volume of patients, the cumulative effect on cash flow and days in accounts receivable becomes material. Practices may find themselves carrying a growing book of anticipated revenue that hasn’t converted yet — not because of clinical or billing errors, but because payer timelines are dictating when care can begin.
The downstream effects extend further. Referrals that stall in the authorization queue may fail to convert into active therapy at all. Patients navigating prolonged approval timelines sometimes abandon treatment or seek care elsewhere, turning a delayed revenue opportunity into a lost one entirely. For specialty practices built around high-value service lines, each of these outcomes carries real financial weight.
This is where authorization complexity stops being an operational nuisance and becomes a barrier to growth. As referral volumes rise, so does the authorization burden. Practices that rely on manual, fragmented workflows often find that scaling patient volume simply scales the delay between care delivery and reimbursement.
The New Federal Deadline Payers Are Now Required to Meet
Beginning Jan. 1, 2026, CMS-0057-F started requiring certain payers to respond to prior authorization requests within federally mandated timelines. Under this new guideline, urgent requests must receive decisions within 72 hours, while standard requests must receive decisions within seven calendar days.
The rule applies to Medicare Advantage, Medicaid, CHIP, and federally facilitated Marketplace plans.
CMS also now requires payers to provide a specific reason when denying a request rather than relying on generic rejection messaging. That change may improve visibility into prior auth denial reasons and appeal rights for providers managing high volumes of specialty requests.
Importantly, the current rule applies primarily to medical items and services, including many infused and injected therapies billed under the medical benefit. A broader extension covering pharmacy-benefit prior authorizations has been proposed but is not yet finalized.
The practical implication is this: The new rule governs how quickly payers must respond rather than how effectively practices submit requests. Incomplete documentation, missing clinical details, or incorrect submissions can still reset the clock entirely. What the rule creates is urgency. Practices that modernize their authorization workflows now are better positioned to meet the new payer timelines and to stop leaving revenue waiting on a clock they don’t control.
Not sure if your workflows are ready? Review the checklist to assess your current authorization processes against the new payer timelines.
The Gap Between Payer Timelines and Practice Workflows
Federal expectations around prior authorization are changing quickly, but most specialty practice workflows haven’t changed with them.
That gap has real consequences. It affects how quickly patients gain access to therapy, how consistently clinics can schedule and deliver treatment, and how efficiently practices convert referrals into revenue-producing care.
For specialty practices managing high volumes of biologic, infused, and injectable therapies, the challenge isn’t just keeping up with payer requirements — it’s building workflows structured to handle both medical and pharmacy benefit authorizations without creating bottlenecks at every step.
CareTria Provider Connect helps specialty practices manage these workflows within a single platform, reducing fragmentation across complex authorization pathways while supporting faster, cleaner submissions.
For specialty clinics navigating growing authorization volume, the question is no longer whether prior authorization creates operational drag, but whether current workflows are built to keep pace with the environment around them.
Ready to learn more about CareTria Provider Connect? Schedule a 1:1 with our team.
FAQ: About Specialty Drug Prior Authorization Delays
Why is specialty drug prior authorization more complex than standard prior authorization?
Specialty therapies often involve higher-cost medications, stricter clinical requirements, and dual medical/pharmacy benefit workflows. Many biologics and infusion therapies also require extensive documentation before approval.
What is the difference between medical and pharmacy benefit authorization?
Medical benefit authorization typically applies to therapies administered in clinical settings, such as infused or injected treatments. Pharmacy benefit authorization generally applies to self-administered medications dispensed through pharmacies.
What are the new CMS prior authorization timelines?
Beginning Jan. 1, 2026, CMS requires affected payers to respond to urgent prior authorization requests within 72 hours and standard requests within seven calendar days.
Does the CMS rule apply to specialty medications?
The current CMS rule primarily applies to medical items and services, including many infused specialty therapies billed under the medical benefit. Pharmacy-benefit drug authorizations are not yet fully included.
How do prior authorization delays affect specialty practice revenue cycles?
Authorization delays can postpone treatment starts, disrupt scheduling, slow reimbursement timing, and reduce referral conversion into active therapy, creating financial strain for specialty practices.
